Home / Business News (page 30)

Business News

Roche to Acquire Cancer Medicine Specialist Ignyta for $1.7 Billion

SAN DIEGO–(BUSINESS WIRE)–Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ …

Read More »

Accenture and Roche Collaborate to Enhance Digital Healthcare for Cancer Patients

NEW YORK–(BUSINESS WIRE)–Accenture (NYSE: ACN) today announced a collaborative services agreement with Roche. Under the terms of this exclusive multi-year agreement, Accenture will provide digital data integration services to Roche’s NAVIFY Tumor Board solution. A tumor board is a meeting in which multi-disciplinary healthcare teams review and discuss individual cancer …

Read More »

Biogen and Ionis Collaborate to Identify Novel Therapies for Treatment of Spinal Muscular Atrophy

CAMBRIDGE, Mass. & CARLSBAD, Calif.–(BUSINESS WIRE)–Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that they have entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy (SMA). Biogen will have the option to license therapies arising out …

Read More »

Array BioPharma and Pfizer Collaborate on Novel Anti-Cancer Combinations

BOULDER, Colo., Dec. 19, 2017 /PRNewswire/ — Array BioPharma (Nasdaq: ARRY) announced today that it has entered into a clinical trial collaboration agreement with Pfizer to investigate the safety and efficacy of several novel anti-cancer combinations, including Array’s MEK inhibitor, binimetinib, with Pfizer’s investigational PARP inhibitor talazoparib, and avelumab*, a …

Read More »

Boehringer Ingelheim and Autifony Collaborate on a Novel Therapeutic Approach to a Range of CNS Disorders

Boehringer Ingelheim and Autifony Therapeutics Limited (“Autifony”) today announced that they have signed an agreement about certain aspects of Autifony’s voltage gated potassium channel modulator platform. Boehringer Ingelheim now has an exclusive option to purchase Autifony’s Kv3.1/3.2 positive modulator platform. Included in the agreement is the lead compound AUT00206, a …

Read More »

Regeneron and ISA Pharmaceuticals Enter Strategic Immuno-Oncology Collaboration

TARRYTOWN, N.Y. and LEIDEN, The Netherlands, Dec. 18, 2017 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced a clinical collaboration to advance ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with cemiplimab (REGN2810), a PD-1 (programmed cell death protein 1) antibody. Regeneron and ISA …

Read More »

GW Pharma Reacquires Full Rights to Develop and Commercialize Sativex in the US

London, UK, 13 Dec 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announces the termination of its previous license agreement with Otsuka Pharmaceutical Co., Ltd. in relation to Sativex®(nabiximols) in the U.S. …

Read More »

Cancer Research UK and Celgene Enter Drug Discovery Collaboration

(Friday) – Cancer Research UK today announced the signing of a five-year drug-discovery collaboration between its subsidiary, Cancer Research Technology (CRT), and Celgene Corporation, to discover, develop and commercialize new anti-cancer treatments. This arrangement represents an expansion of Cancer Research Technology’s theme-based translational model that now encompasses six industry partnerships, including …

Read More »

Daiichi Sankyo and Puma Collaborate with Major Cancer Center in HER2-Mutated Cancer

TOKYO, BASKING RIDGE, N.J. & LOS ANGELES–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Puma Biotechnology, Inc. (Nasdaq: PBYI) have announced a preclinical research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to explore the combination of Daiichi Sankyo’s investigational antibody drug conjugate DS-8201 and Puma Biotechnology’s irreversible pan-HER …

Read More »

Vertex and CRISPR Therapeutics Partner to Develop CTX001 as CRISPR/Cas9 Gene Edited Treatment

BOSTON, CAMBRIDGE, Mass. & ZUG, Switzerland–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) today announced that the companies will co-develop and co-commercialize CTX001, an investigational gene editing treatment, as part of the companies’ previously announced collaboration aimed at the discovery and development of new gene editing treatments …

Read More »